Asunaprevir
ANTIINFECTIVES FOR SYSTEMIC USE
Also known as: BMS-650032, sunvepra
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Asunaprevir is a drug catalogued in DrugCentral. It was first approved by the PMDA in 2014. DrugCentral lists 4 molecular targets, including Genome polyprotein, pol and NS3. Recorded indications include Chronic hepatitis C.
- Molecular targets: Genome polyprotein, pol, NS3 and NS3 (4 listed in DrugCentral).
- Indications: Chronic hepatitis C.
- ATC code: J05AP06 (Antivirals for treatment of HCV infections).
- Molecular formula: C35H46ClN5O9S; molecular weight 748.29 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Chronic hepatitis C
Mechanism & targets
Molecular targets (4)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Genome polyprotein | — | inhibitor | Ki 9.40 |
| Integrase | pol | unknown | IC50 9.00 |
| NS3 | NS3 | unknown | EC50 8.92 |
| Genome polyprotein | NS3 | unknown | EC50 8.92 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2014-07-04 | PMDA | — | — |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
J05AP06 | ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HCV infections |
J05AP58 | ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HCV infections |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Virologic failure | 306.2 |
| Viral mutation identified | 283.8 |
| Alanine aminotransferase increased | 133.0 |
| Hepatocellular carcinoma | 130.9 |
| Liver injury | 82.8 |
| Hepatitis B reactivation | 80.0 |
| Hepatic function abnormal | 79.9 |
| Hepatitis B DNA increased | 65.1 |
| Ascites | 61.6 |
| Hepatic failure | 61.4 |
| Renal impairment | 58.1 |
| Pyrexia | 53.5 |
Chemical structure
| Molecular formula | C35H46ClN5O9S |
|---|---|
| Molecular weight | 748.29 g/mol |
| CAS number | 630420-16-5 |
| InChIKey | XRWSZZJLZRKHHD-WVWIJVSJSA-N |
| PubChem CID | 16076883 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Asunaprevir used for?
DrugCentral lists the following indications for Asunaprevir: Chronic hepatitis C.
How does Asunaprevir work?
Its molecular targets in DrugCentral include Genome polyprotein (inhibitor), pol, NS3 and NS3.
When was Asunaprevir first approved?
Asunaprevir was first approved by the PMDA in 2014.
What is the chemical formula of Asunaprevir?
Asunaprevir has the molecular formula C35H46ClN5O9S and a molecular weight of 748.29 g/mol.
Browse: all drugs starting with A · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4889 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL2105735 — compound record and bioactivity
- PubChem CID 16076883 — chemical identifiers
- DrugBank DB11586 — drug record
- FDA UNII S9X0KRJ00S — substance identity
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.